<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02500004</url>
  </required_header>
  <id_info>
    <org_study_id>142071</org_study_id>
    <secondary_id>NL51402.068.14</secondary_id>
    <nct_id>NCT02500004</nct_id>
  </id_info>
  <brief_title>Brown Adipose Tissue Activity and Energy Metabolism in Cachexia</brief_title>
  <acronym>BAT-Cachexia</acronym>
  <official_title>Brown Adipose Tissue Activity and Energy Metabolism in Cachexia Induced by Cancer or Chronic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study BAT activity and energy metabolism in patients with cachexia induced by cancer or
      chronic disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, cross-sectional study to determine BAT activity in cachectic patients
      with pancreatic or non-small cell lung cancer, and in cachectic patients with chronic
      obstructive pulmonary disease (COPD), and compare results with healthy individuals and
      non-cachectic COPD patients, matched for age and BMI.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brown adipose tissue (BAT) activity measured by PET(-MRI)</measure>
    <time_frame>participants will be followed for 2 weeks</time_frame>
    <description>The main endpoint of this study is BAT volume and intensity of activity in Standard Uptake Value (SUV) in the presence of cancer cachexia, COPD cachexia, and compared to non-cachectic COPD patients and healthy individuals, as assessed by 18F-fluoro-deoxyglucose (18F-FDG) PET-MRI scanning.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total energy metabolism measured by resting energy expenditure (REE) and doubly labeled water</measure>
    <time_frame>participants will be followed for 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting metabolic rate measured by REE</measure>
    <time_frame>participants will be followed for 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic gene expression in WAT measured by biopsy of subcutaneous fat</measure>
    <time_frame>participants will be followed for 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic inflammatory status measured in blood</measure>
    <time_frame>participants will be followed for 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat tissue mass measured by MRI, DXA, and doubly labeled water</measure>
    <time_frame>participants will be followed for 2 weeks</time_frame>
    <description>Detailed body composition phenotyping of cachexia by (PET-)MRI to compare with commonly applied clinical measures (D2O and DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal status measured in blood</measure>
    <time_frame>participants will be followed for 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lean tissue mass measured by MRI, DXA, and doubly labeled water</measure>
    <time_frame>participants will be followed for 2 weeks</time_frame>
    <description>Detailed body composition phenotyping of cachexia by (PET-)MRI to compare with commonly applied clinical measures (D2O and DXA)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cachexia</condition>
  <condition>Neoplasms</condition>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Cachectic pancreatic cancer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cachectic patients with pancreatic cancer
BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cachectic NSCLC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cachectic patients with non-small cell lung cancer
BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cachectic COPD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cachectic COPD patients.
BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-cachectic COPD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-cachectic COPD patients.
BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy individuals</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>18F-FDG PET-MRI-imaging</intervention_name>
    <description>BAT activity: 18F-FDG PET-MRI-imaging.</description>
    <arm_group_label>Cachectic pancreatic cancer</arm_group_label>
    <arm_group_label>Cachectic NSCLC</arm_group_label>
    <arm_group_label>Cachectic COPD</arm_group_label>
    <arm_group_label>Non-cachectic COPD</arm_group_label>
    <arm_group_label>Healthy individuals</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>DXA scanning</intervention_name>
    <description>Body composition: DXA scanning, D2O and MRI.</description>
    <arm_group_label>Cachectic pancreatic cancer</arm_group_label>
    <arm_group_label>Cachectic NSCLC</arm_group_label>
    <arm_group_label>Cachectic COPD</arm_group_label>
    <arm_group_label>Non-cachectic COPD</arm_group_label>
    <arm_group_label>Healthy individuals</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Abdominal subcutaneous adipose tissue biopsy</intervention_name>
    <description>Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.</description>
    <arm_group_label>Cachectic pancreatic cancer</arm_group_label>
    <arm_group_label>Cachectic NSCLC</arm_group_label>
    <arm_group_label>Cachectic COPD</arm_group_label>
    <arm_group_label>Non-cachectic COPD</arm_group_label>
    <arm_group_label>Healthy individuals</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Systemic inflammatory profile: blood sampling.</description>
    <arm_group_label>Cachectic pancreatic cancer</arm_group_label>
    <arm_group_label>Cachectic NSCLC</arm_group_label>
    <arm_group_label>Cachectic COPD</arm_group_label>
    <arm_group_label>Non-cachectic COPD</arm_group_label>
    <arm_group_label>Healthy individuals</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Indirect calorimetry</intervention_name>
    <description>Resting metabolic rate: indirect calorimetry.</description>
    <arm_group_label>Cachectic pancreatic cancer</arm_group_label>
    <arm_group_label>Cachectic NSCLC</arm_group_label>
    <arm_group_label>Cachectic COPD</arm_group_label>
    <arm_group_label>Non-cachectic COPD</arm_group_label>
    <arm_group_label>Healthy individuals</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Accelerometry</intervention_name>
    <description>Physical activity level: accelerometry.</description>
    <arm_group_label>Cachectic pancreatic cancer</arm_group_label>
    <arm_group_label>Cachectic NSCLC</arm_group_label>
    <arm_group_label>Cachectic COPD</arm_group_label>
    <arm_group_label>Non-cachectic COPD</arm_group_label>
    <arm_group_label>Healthy individuals</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Double-labeled water</intervention_name>
    <description>Body composition: DXA scanning, D2O and MRI. Total daily energy expenditure: double-labeled water.</description>
    <arm_group_label>Cachectic pancreatic cancer</arm_group_label>
    <arm_group_label>Cachectic NSCLC</arm_group_label>
    <arm_group_label>Cachectic COPD</arm_group_label>
    <arm_group_label>Non-cachectic COPD</arm_group_label>
    <arm_group_label>Healthy individuals</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pancreatic cancer patients, or NSCLC cancer patients, or COPD patients

          -  The diagnostic criterion for cachexia is unintentional weight loss more than 5% over
             the past 6 months or more than 2% in individuals with a body-mass index &lt; 20 kg/m2 and
             muscle wasting assessed by DXA;

          -  Age ≥ 30 years;

          -  Gender: male and female;

          -  Caucasians.

        Exclusion Criteria:

          -  Uncontrolled Diabetes Mellitus;

          -  Patients with severe clotting disorder;

          -  Patients with an active second malignancy;

          -  Psychological unstable persons presumed unfit to perform the measurements, including
             claustrophobia;

          -  Persons unable to lie or sit still for 1-2 hours;

          -  Oxygen therapy;

          -  Pregnant subjects;Subjects unable to undergo MRI (e.g. pacemaker; neurostimulator;
             implantable cardioverter-defibrillator (ICD) or leads; Foley bladder catheter;
             medication pump; cochlear or hearing implant; tattoos or other items that cannot be
             removed and include metal parts (for instance from operations in the past); metal
             splinter in the eye; vascular clips; denture, which contains magnets);

          -  Subjects that received high doses of radiotherapeutic radiation of the neck and/or
             upper chest in their medical history;

          -  Persons that received cervical or thoracic sympathectomy or have a nerve dysfunction
             which is likely to influence sympathetic nerves;

          -  The use of medication that influences the sympathetic nerve system: ß-blockers,
             α-blockers, central anti-hypertensives, certain anti-depression drugs (MAO inhibitors,
             tricyclic anti-depressives), reserpine, cocaine, calciumblockers, labetalol, and
             certain tranquillizers (fenothiazines).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annemie Schols, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht UMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judith de Vos, MD</last_name>
    <phone>0031 43 3872001</phone>
    <email>judith.de.vos@mumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karin Sanders, MD</last_name>
    <phone>0031 43 3884597</phone>
    <email>k.sanders@maastrichtuniversity.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maastricht UMC+</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith de Vos-Geelen, MD</last_name>
      <phone>0031 43 3872001</phone>
      <email>judith.de.vos@mumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Karin Sanders, MD</last_name>
      <phone>0031 43 3884597</phone>
      <email>k.sanders@maastrichtuniversity.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>July 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2015</study_first_posted>
  <last_update_submitted>March 29, 2016</last_update_submitted>
  <last_update_submitted_qc>March 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Cachexia</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

